2024 World Conference on Lung Cancer (WCLC) - ePosters-EP.12A.19 Race May Affect Survival in 1L Patients with Metastatic Non-Small Cell Lung Cancer (mNSLC) Onegfr-Targeted Therapy

EP.12A.19 Race May Affect Survival in 1L Patients with Metastatic Non-Small Cell Lung Cancer (mNSLC) Onegfr-Targeted Therapy

Back to course

Pdf Summary

A retrospective study analyzed the impact of race on survival outcomes among patients with metastatic Non-small Cell Lung Cancer (mNSCLC) treated with first-line EGFR tyrosine kinase inhibitors (TKIs), emphasizing diversity in mutations and treatment responses. The study, conducted at a single institution, examined 315 patients with classical EGFR mutations and 36 patients with atypical mutations, treated between 2007 and 2023. The analysis focused on three groups - White, Asian, and Black patients - and compared median progression-free survival (mPFS) and overall survival (mOS) based on different EGFR-targeted therapies like osimertinib, afatinib, and erlotinib.<br /><br />Key findings indicated no significant differences in demographic variables among the racial groups, but disparities were noted in treatment outcomes. Classical mutations were associated with better mPFS and mOS compared to atypical mutations. Among those with atypical mutations, osimertinib showed superior efficacy compared to afatinib or erlotinib.<br /><br />By race, Black patients had inferior mPFS and trends towards inferior mOS compared to White and Asian patients when treated with erlotinib or osimertinib. Asians tended to have superior mOS and PFS. Overall, the study highlighted racial disparities in survival outcomes, potentially driven by genetic or socioeconomic factors. Future research aims to validate these disparities using a larger, real-world dataset. The study underscores the importance of considering racial and genetic variables in treatment approaches for mNSCLC to improve patient outcomes.

Asset Subtitle

Melina Marmarelis

Meta Tag

Speaker Melina Marmarelis

Topic Metastatic Non-small Cell Lung Cancer – Targeted Therapy

Keywords

retrospective study

metastatic Non-small Cell Lung Cancer

EGFR tyrosine kinase inhibitors

racial disparities

survival outcomes

classical mutations

atypical mutations

osimertinib

progression-free survival

overall survival